• Sonuç bulunamadı

Evaluation of Octreotide-Conjugated Liposomal Cantharidin in Hyperbaric Oxygen Environment Treating for Breast Cancer

N/A
N/A
Protected

Academic year: 2021

Share "Evaluation of Octreotide-Conjugated Liposomal Cantharidin in Hyperbaric Oxygen Environment Treating for Breast Cancer"

Copied!
1
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

鍵結體抑素類似物之微脂粒斑蝥素並於高壓氧環境對於乳癌之治療 與評估

Evaluation of Octreotide-Conjugated Liposomal Cantharidin in Hyperbaric Oxygen Environment Treating for Breast Cancer

中文摘要

微脂粒應用在癌症化學治療上有許多的研究,並且有少數上市的產品。因此,具標靶的微脂粒 配方化療藥物還是值得研究。

在此研究,設計標靶微脂粒,在表面鍵結體抑素的類似物,Octreotide,利用其和特定腫瘤細 胞有專一性結合的特性,並且引起胞飲作用,增加藥物進入腫瘤,增加藥效。

當高壓氧造成血管及細胞增生使腫瘤組織血流量增加,使到達腫瘤的藥物量增加。當細胞受氧 刺激活化後,胞吞藥物增加。當高壓氧展現抑制乳癌細胞、血管增生時,也視為輔助化療藥物的 效果。

斑蝥素在細胞實驗中有明顯抗癌的功能。但是應用在動物實驗中,面臨了高劑量易致死,低劑 量無效的問題。因此,在動物實驗中,將斑蝥素包覆在微脂粒中,成功克服易致死的問題,並 且發現明顯減少腫瘤體積。

「高壓氧」及「Octreotide 鍵結微脂粒」,的確增加斑蝥素的細胞毒性。

微脂粒配方的斑蝥素克服斑蝥素的體內毒性,並且明顯降低腫瘤體積。

英文摘要

Referanslar

Benzer Belgeler

When hyperbaric oxygen demonstrated inhibition of breast cancer cells, angiogenesis, we also considered the effect of chemotherapy drugs.. Cantharidin in cancer cells in

Evaluation of Octreotide-Conjugated Liposomal Cantharidin in Hyperbaric Oxygen Environment Treating for Breast

In our study the mean time between the diagnosis of breast cancer and detection of malignant pulmonary pathology was 4.8±4.2 (0.3-15.0) years.. However there are studies reporting

Hyperbaric oxygen therapy has proved itself useful as an adjuvant treatment for chronic ulcers and is highly recommended by several medical associations.. HBOT should be prefer- red

The high oxygen pressure in the blood not only serves for an increase in the tissue oxygenation but also has numerous other effects: in cases of gaseous gangrene inhibi- tion

A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy

Our results revealed that HBO treatment increased significantly the genotoxic effects in peripheral blood lymphocytes after the first session of therapy.. BNMN:

Of the patients who received the neoadjuvant chemotherapy, full response in the right breast and partial response in the left breast were obtained in two of them; one patient